I was thinking more along the lines of the Flaskworks device. Besides the obvious advantages of cost and repeatability having a microchip based device process the tumor may enable said fine tuning to the mutations/DNA (or other factors) of the tumor resulting in a more efficacious vaccine. With the delay in getting to this point as a shareholder it would appease me somewhat to find out that there is a “method B” or a pathway to a “method B” is being worked for L.